Prostate-specific antigen testing and opportunistic prostate cancer screening - CAP intervention.

Clift et al 1 aimed to estimate prostate-specific antigen (PSA) contamination in the control arm of the CAP prostate cancer screening trial, concluding that there is ‘limited plausibility of deriving clear conclusions from trials of PSA screening’ . However, their conclusion failed to acknowledge that the CAP intervention significantly increased prostate cancer detection: during the first 18 months following …